Dexcom (DXCM) stock is down over 40% in Friday's session after the continuous glucose monitoring technology company fell short of revenue estimates for its second quarter and slashed its full-year revenue forecast.
In the three months ended June 30, Dexcom's revenue increased 15.3% year-over-year to $1 billion, due mostly to 18.7% growth in the U.S. market to $731.9 million. Its earnings per share (EPS) increased 26.5% from the year-ago period to 43 cents.
"While Dexcom advanced several key strategic initiatives in the second quarter, our execution did not meet our high standards," said Dexcom CEO Kevin Sayer in a statement. "We have a unique opportunity to serve millions of more customers around the world with our differentiated product portfolio and we are taking action to improve our execution and best position ourselves for continued long-term growth."
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
The results were mixed compared with analysts' expectations. Wall Street was anticipating revenue of $1.04 billion and earnings of 39 cents per share, according to CNBC.
The sentiment worsened when Dexcom lowered its full-year revenue forecast. The company now anticipates revenue in the range of $4 billion to $4.05 billion in fiscal 2024, down from its previous forecast of $4.2 billion to $4.35 billion.
For the third quarter, Dexcom expects revenue in the range of $975 million to $1 billion, which it said accounts for "certain unique items impacting 2024 seasonality," including a reorganization of its sales team and lower revenue per user.
Analysts were anticipating revenue of $1.15 billion for the third quarter and $4.3 billion for the full year, according to Yahoo Finance.
Is Dexcom stock a buy, sell or hold?
Wall Street is bullish on the healthcare stock. According to S&P Global Market Intelligence, the average analyst target price for DXCM stock is $102.88, representing implied upside of more than 60% to current levels. Additionally, the consensus recommendation is a Buy.
However, analysts may very well revise their targets lower and reduce their ratings in the days and weeks ahead following the earnings results.
Financial services firm Jefferies is one that already adjusted its price target on Dexcom, lowering it to $100 from $160 while maintaining its Buy rating.
"DXCM cited execution issues in Q2 and expects issues around sales force disruption, channel mix, and rebates to persist through the year and recovery in 2025," said Jefferies analyst Matthew Taylor. "We do not see the DXCM issues as related to market demand or competition, believing they are mostly execution based and 'fixable' over time."
Related Content
-
Return to Your Home Country to Retire: Repatriation RetirementThey came to the U.S. to live and work, but they want to retire in the old country. Here's how to juggle the move back home.
-
How Much Does Being Rich Matter in Retirement? Less Than You Might ThinkAfter a certain point, having more money in retirement won't make you any happier, new research shows. Instead, physical health, a sense of purpose, and a minimal amount of non-mortgage debt are more relevant.
-
How Much Does Being Rich Matter in Retirement?After a certain point, having more money in retirement won't make you any happier, new research shows. Instead, physical health, a sense of purpose, and a minimal amount of non-mortgage debt are more relevant.
-
The Three Biggest Fears Keeping Retirees Up at NightHere are the steps you can take to put those fears to rest and retire with confidence so you can relax and enjoy the life you've planned.
-
What Can a Donor-Advised Fund Do for You? (A Lot)DAFs and private foundations go about helping charities (and those who donate) in different ways. Each comes with its own benefits and restrictions to navigate.
-
Estate Planning When You Have International AssetsEstate planning gets tricky when you have assets and/or beneficiaries outside the U.S. To avoid costly inheritance mistakes, it pays to understand the basics.
-
Microsoft Stock: Innovation Spurs Its 100,000% ReturnMicrosoft's ability to recognize the "next big thing" has allowed sales – and its share price – to grow exponentially over the years.
-
Three Essential Estate Planning Steps to Protect Your Nest EggAfter dedicating years to building your wealth and securing your future, make sure your assets are protected and your loved ones are provided for in the future.
-
Is Chasing the American Dream Ruining Your Financial Life?Too many people focus on visible affluence as a marker of success. Here's how to avoid succumbing to the pressure and driving yourself into debt.
-
Stock Market Today: Dow Sinks 715 Points as Inflation Unrest GrowsInflation worries are showing up in both hard and soft data.
